Cover Image
市場調查報告書

注射型藥物遞輸的全球市場:不同設備,治療藥·處方 (自行注射設備,自體免疫疾病,糖尿病,腫瘤,荷爾蒙失調,微脂體,微球,奈米粒子,高分子微胞)

Injectable Drug Delivery Market: By Devices, Therapeutics & Formulations [Self-Injection Devices (Pen, Needle Free & Auto Injectors) Auto-Immune Diseases, Diabetes, Oncology, Hormonal Disorders, Liposomes, Microspheres, Others]-Forecast(2015-2020)

出版商 IndustryARC 商品編碼 351132
出版日期 內容資訊 英文 165 Pages
訂單完成後即時交付
價格
Back to Top
注射型藥物遞輸的全球市場:不同設備,治療藥·處方 (自行注射設備,自體免疫疾病,糖尿病,腫瘤,荷爾蒙失調,微脂體,微球,奈米粒子,高分子微胞) Injectable Drug Delivery Market: By Devices, Therapeutics & Formulations [Self-Injection Devices (Pen, Needle Free & Auto Injectors) Auto-Immune Diseases, Diabetes, Oncology, Hormonal Disorders, Liposomes, Microspheres, Others]-Forecast(2015-2020)
出版日期: 2015年01月06日 內容資訊: 英文 165 Pages
簡介

自行注射設備預測在2013∼2018年間將以16.6%的速度成長。傳統的注射設備雖仍保有市場87%的佔有率,但預計自行注射設備的使用在今後5年將會持續擴大,到2018年傳統的注射設備將減少到83%。

本報告提供全球注射型藥物遞輸市場現狀與今後的市場成長預測,彙整不同設備,治療藥·處方趨勢,各地區分析,以及打入市場的主要企業簡介。

第1章 市場概要

第2章 摘要整理

第3章 市場情況

  • 市場佔有率分析
  • 競爭分析
    • 產品基準
    • 終端用戶分析
    • 專利分析
    • 前五名公司財務分析

第4章 市場力量

  • 推動市場的要素
    • 生技藥品和注射型藥物遞輸設備的傳統使用
    • 全球性糖尿病患者的增加和胰島素筆針的使用增加
    • 其他
  • 市場抑制力
    • 感染風險與政府的法律
    • 其他
  • 市場課題
    • 為了避免產品回收所需的高製造標準
    • 其他
  • 該產業的魅力

第5章 策略性分析

  • 價值鏈分析
  • 機會分析
  • 產品生命週期

第6章 各類型

  • 醫藥品處方
  • 不同設備
    • 傳統設備
    • 自動注射器
    • 自行注射設備
    • 筆型注射器
    • 無針頭注射設備
  • 其他

第7章 各疾病類型

  • 貧血
  • 糖尿病
  • 多發性硬化症
  • 類風濕性關節炎
  • 克隆氏症
  • 其他

第8章 各地區分析

  • 簡介
  • 北美
  • 中南美
  • 歐洲
  • 亞太地區
  • 其他

第9章 市場熵

第10章 企業簡介

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The Global Injectable Drug Delivery Devices Market has been analyzed with respect to the demand for devices from different countries across the globe. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2020. The drug injection devices market has been segmented into conventional injectors and self-injection devices broadly. Similarly the drug formulations market has been segmented into the conventional drugs and novel drugs segments. The therapeutic areas are further segmented and analyzed in this report.

While conventional devices are growing at a CAGR of 7.37%, self-injection devices are expected to grow at 16.6% during 2013 - 2018. Conventional injection devices hold around 87% market share currently but this is expected to decrease to around 83% by 2018, as the use of self-injection devices increases in the next 5 years.

The global injectable drug delivery devices market is expected to increase from around $ 11.6 bn in 2013 to around $ 17.5 bn in 2018. Self-injection devices are expected to grow at the highest growth rate of 16.1% with conventional injection devices growing at only 7.4% during the forecast period 2013 - 2018.

Analyzing the competitive landscape of the global conventional injectable devices market for 2012 IndustryARC is of the opinion that Becton Dickinson & Co. had the top position with a market share of around 27% followed by Baxter International Inc with a share of 23%. Overall these two companies along with Terumo Corporation and Schott AG together held market share of around 85%.

Table of Contents

1. Injectable Drug Delivery Market Overview

2. Executive Summary

3. Injectable Drug Delivery Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End user profiling
    • 3.2.3. Patent Analysis
    • 3.2.4. Top 5 Financials Analysis

4. Injectable Drug Delivery Market Forces

  • 4.1. Market Drivers
    • 4.1.1. Inherent Use Case Scenario of IDD Devices With Biologics
    • 4.1.2. Increase in Global Diabetic Population and Usage of Insulin Pens
    • 4.1.3. Others
  • 4.2. Market Constraints
    • 4.2.1. Infection Risks And Government Laws
    • 4.2.2. Others
  • 4.3. Market Challenges
    • 4.3.1. Higher Manufacturing Standards Needed to Avoid Product Recalls
    • 4.3.2. Others
  • 4.4. Attractiveness of the Industry
    • 4.4.1. Power of Suppliers
    • 4.4.2. Power of Customers
    • 4.4.3. Threat of New entrants
    • 4.4.4. Threat of Substitution
    • 4.4.5. Degree of Competition

5. Injectable Drug Delivery Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Opportunities Analysis
  • 5.3. Product/Market Life Cycle Analysis

6 GLOBAL INJECTABLE DRUG DELIVERY - MARKET BY DELIVERY DEVICES

  • 6.1 MARKET OVERVIEW
  • 6.2 CONVENTIONAL INJECTION DEVICES MARKET
  • 6.3 SELF-INJECTION DEVICES MARKET
  • 6.4 OTHER INJECTION DEVICES MARKET
  • 6.5 AUTO DRUG INJECTING DEVICES
    • 6.5.1 BY DRUG LOADING
      • 6.5.1.1 Prefilled Auto Injectors
      • 6.5.1.2 Fillable Auto Injectors
      • 6.5.1.3 By User Intervention
      • 6.5.1.4 Automated Auto Injectors
      • 6.5.1.5 Manual Auto Injectors
      • 6.5.1.6 By Design
      • 6.5.1.6.1. Standard Auto Injectors
      • 6.5.1.6.2. Customized Auto Injectors
      • 6.5.1.7. By Reusability
      • 6.5.1.7.1. Disposable Auto Injectors
      • 6.5.1.7.2. Reusable Auto Injectors
  • 6.6 PEN INJECTORS
    • 6.6.1 BY PRODUCT
      • 6.6.1.1 Single Chamber Pen Injectors
      • 6.6.1.2 Dual Chamber Pen Injectors
    • 6.6.2 BY REUSABILITY
      • 6.6.2.1 Disposable Pen Injectors
      • 6.6.2.2 Reusable Pen Injectors
    • 6.6.3 BY DESIGN
      • 6.6.3.1 Standardized Pen Injectors
      • 6.6.3.2 Customized Pen Injectors
  • 6.7 NEEDLE FREE DRUG INJECTION DEVICES
    • 6.7.1 BY DRUG LOADING
      • 6.7.1.1 Prefilled Needle Free Injectors
      • 6.7.1.2 Fillable Needle Free Injectors
    • 6.7.2 BY TECHNOLOGY
      • 6.7.2.1 Jet-Based Needle-Free Injectors
      • 6.7.2.2 Spring-Based Needle-Free Injectors
      • 6.7.2.3 Laser-Based Needle Free Injectors
      • 6.7.2.4 Vibration-Based Needle Free Injectors
    • 6.7.3 BY REUSABILITY
      • 6.7.3.1 Disposable Needle Free Injectors
      • 6.7.3.2 Reusable Needle Free Injectors
  • 6.8 CONVENTIONAL DRUG INJECTION DEVICES
    • 6.8.1 BY REUSABILITY
      • 6.8.1.1 Disposable Injection Devices
      • 6.8.1.2 Reusable Injection Devices
    • 6.8.2 BY MATERIAL
      • 6.8.2.1 Glass Based Injectors
      • 6.8.2.2 Plastic Based Injectors
    • 6.8.3 BY DRUG LOADING
      • 6.8.3.1 Prefilled Injection Devices
      • 6.8.3.2 Fillable Injection Devices

7 GLOBAL INJECTABLE DRUG DELIVERY MARKET - BY DRUG FORMULATIONS

  • 7.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
    • 7.1.1 INJECTABLE DRUG DELIVERY FORMULATION SOLUTIONS
    • 7.1.2 RECONSTITUTED DRUG DELIVERY FORMULATION SOLUTIONS
  • 7.2 NOVEL DRUG DELIVERY FORMULATION SOLUTIONS
    • 7.2.1 LIPOSOMAL SYSTEMS
    • 7.2.2 MICROSPHERES
    • 7.2.3 NANOPARTICLES
    • 7.2.4 POLYMERIC MICELLES
    • 7.2.5 OTHERS

8 GLOBAL INJECTABLE DRUG DELIVERY MARKET - BY THERAPEUTIC AREAS

  • 8.1 AUTO-IMMUNE DISEASES
    • 8.1.1 MULTIPLE SCLEROSIS
    • 8.1.2 RHEUMATOID ARTHRITIS
    • 8.1.3 CROHN'S DISEASES
    • 8.1.4 PSORIASIS
    • 8.1.5 OTHERS
  • 8.2 HORMONAL DISORDERS
    • 8.2.1 DIABETES
    • 8.2.2 ANEMIA
    • 8.2.3 REPRODUCTIVE HEALTH DISEASES
    • 8.2.4 OSTEOPOROSIS
    • 8.2.5 GROWTH HORMONE DEFICIENCY
    • 8.2.6 ANTITHROMBOTIC THERAPY
  • 8.3 ORPHAN OR RARE DISEASES
  • 8.4 ONCOLOGY
  • 8.5 OTHERS
    • 8.5.1 PAIN MANAGEMENT
    • 8.5.2 HEPATITIS C
    • 8.5.3 ALLERGIES
    • 8.5.4 AESTHETIC TREATMENT

9 GLOBAL INJECTABLE DRUG DELIVERY MARKET - GEOGRAPHICAL ANALYSIS

  • 9.1 NORTH AMERICA
  • 9.2 EUROPE
  • 9.3 ASIA PACIFIC
  • 9.4 REST OF WORLD

10. Injectable Drug Delivery Market Entropy

  • 10.1. New Product Launches
  • 10.2. M&As, Collaborations, JVs and Partnerships

11. Injectable Drug Delivery Market Company Profiles (Overview, Financials, SWOT Analysis - Top 5 Companies, Developments, Product Portfolio)

  • 11.1. Becton Dickinson and Company (BD)
  • 11.2. Baxter International Inc.
  • 11.3. Consort Medical PLC
  • 11.4. Crossject SA
  • 11.5. Eli Lilly and Company
  • 11.6. Elcam Medical
  • 11.7. Novo Nordisk
  • 11.8. Owen Mumford Ltd
  • 11.9. Sanofi
  • 11.10. Schott AG
  • 11.11. Terumo Corporation
  • 11.12. Ypsomed Holding AG
  • 11.13. Others

More than 40 Companies are profiled in this Research Report, Complete List available on Request.*

"*Financials would be provided on a best efforts basis for private companies."

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top